National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13 17 Years United States, 2016
The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents routinely receive tetanus, diphtheria, and acellular pertussis vaccine (Tdap) meningococcal conjugate vaccine (MenACWY) and human papillomavirus (HPV) vaccine (1) at age 11 12 years. ACIP also recommends catch up vaccination with hepatitis B vaccine, measles, mumps, and rubella (MMR) vaccine, and varicella vaccine for adolescents who are not up to date with childhood vaccinations. ACIP recommends a booster dose of MenACWY at age 16 years (1) In December 2016, ACIP updated HPV vaccine recommendations to include a 2 dose schedule for immunocompetent adolescents initiating the vaccination series before their 15th birthday (2) To estimate adolescent vaccination coverage in the United States, CDC analyzed data from the 2016 National Immunization Survey Teen (NIS Teen) for 20,475 adolescents aged 13 17 years. During 2015 2016, coverage increased for =1 dose of Tdap (from 86.4% to 88.0% and for each HPV vaccine dose (from 56.1% to 60.4% for =1 dose) Among adolescents aged 17 years, coverage with =2 doses of MenACWY increased from 33.3% to 39.1% In 2016, 43.4% of adolescents (49.5% of females; 37.5% of males) were up to date with the HPV vaccination series, applying the updated HPV vaccine recommendations retrospectively. Coverage with =1 HPV vaccine dose varied by metropolitan statistical area (MSA) status and was lowest (50.4% among adolescents living in non MSA areas and highest (65.9% among those living in MSA central cities.SS Adolescent vaccination coverage continues to improve overall; however, substantial opportunities exist to further increase HPV associated cancer prevention.
MMWR. Morbidity and mortality weekly report